Maria Stefania Sciallero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3029768/publications.pdf

Version: 2024-02-01

49 papers

1,743 citations

³⁶¹⁴¹³
20
h-index

265206 42 g-index

51 all docs

51 docs citations

51 times ranked

2191 citing authors

#	Article	IF	CITATIONS
1	Once-Only Sigmoidoscopy in Colorectal Cancer Screening: Follow-up Findings of the Italian Randomized Controlled Trial-SCORE. Journal of the National Cancer Institute, 2011, 103, 1310-1322.	6.3	539
2	Baseline Findings of the Italian Multicenter Randomized Controlled Trial of "Once-Only Sigmoidoscopy"SCORE. Journal of the National Cancer Institute, 2002, 94, 1763-1772.	6.3	206
3	Interobserver agreement in the histologic diagnosis of colorectal polyps the experience of the multicenter adenoma colorectal study (SMAC). Journal of Clinical Epidemiology, 2003, 56, 209-214.	5.0	83
4	Flow cytometric DNA index in the prognosis of colorectal cancer. Cancer, 1991, 67, 1921-1927.	4.1	77
5	<i>CDKN2A</i> is the main susceptibility gene in Italian pancreatic cancer families. Journal of Medical Genetics, 2012, 49, 164-170.	3.2	64
6	A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunology, Immunotherapy, 2013, 62, 1041-1052.	4.2	55
7	DNA flow cytometry of endoscopically examined colorectal adenomas and adenocarcinomas. Cytometry, 1988, 9, 238-244.	1.8	54
8	Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. European Journal of Gastroenterology and Hepatology, 1997, 9, 881-885.	1.6	50
9	Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas. Gastrointestinal Endoscopy, 1997, 46, 124-130.	1.0	42
10	Flow cytometric DNA ploidy in colorectal adenomas and family history of colorectal cancer. Cancer, 1988, 61, 114-120.	4.1	40
11	First-line single-agent cetuximab in patients with advanced colorectal cancer. Annals of Oncology, 2008, 19, 711-716.	1.2	40
12	Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). ESMO Open, 2017, 2, e000147.	4.5	36
13	Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. Familial Cancer, 2009, 8, 547-553.	1.9	34
14	Novel germlineAPC variants in patients with multiple adenomas. Genes Chromosomes and Cancer, 1998, 22, 257-267.	2.8	33
15	Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. Familial Cancer, 2012, 11, 41-47.	1.9	32
16	HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer. JAMA Oncology, 2019, 5, 605.	7.1	32
17	Long-Term Follow-up of the Italian Flexible Sigmoidoscopy Screening Trial. Annals of Internal Medicine, 2022, 175, 36-45.	3.9	25
18	Referral of Ovarian Cancer Patients for Genetic Counselling by Oncologists: Need for Improvement. Public Health Genomics, 2015, 18, 225-232.	1.0	23

#	Article	IF	Citations
19	"Present and future of immunotherapy in Neuroendocrine Tumors". Reviews in Endocrine and Metabolic Disorders, 2021, 22, 615-636.	5 . 7	21
20	The Clinical Significance of Gastric Epithelial Dysplasia. Endoscopy, 1986, 18, 174-176.	1.8	20
21	Do patients with rectosigmoid adenomas 5 mm or less in diameter need total colonoscopy?. Gastrointestinal Endoscopy, 1999, 50, 314-321.	1.0	20
22	Predictive value of rectal bleeding for distal colonic neoplastic lesions in a screened population. European Journal of Cancer, 2004, 40, 245-252.	2.8	20
23	Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1. Cancers, 2020, 12, 1007.	3.7	19
24	Predicting Proximal Advanced Neoplasms at Screening Sigmoidoscopy. Diseases of the Colon and Rectum, 2004, 47, 1331-1340.	1.3	17
25	DNA aneuploidy is an independent factor of poor prognosis in pancreatic and peripancreatic cancer. International Journal of Gastrointestinal Cancer, 1993, 14, 21-28.	0.4	16
26	Prevalence of the E1317Q Variant of the APC Gene in Italian Patients with Colorectal Adenomas. Genetic Testing and Molecular Biomarkers, 2002, 6, 313-317.	1.7	16
27	Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. Annals of Oncology, 2011, 22, 973-978.	1.2	15
28	DNA Content Analysis of Barrett's Esophagus by Flow Cytometry. Endoscopy, 1993, 25, 648-651.	1.8	14
29	Gastroesophageal reflux disease: relationship between clinical and histological features. GOSPE. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago. Digestive Diseases and Sciences, 1999, 44, 2412-2418.	2.3	14
30	Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 4709.	4.1	13
31	DNA Flow Cytometry of Endoscopically Examined Colorectal Adenocarcinomas. Pathology Research and Practice, 1989, 185, 589-593.	2.3	11
32	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. ESMO Open, 2020, 5, e001001.	4.5	11
33	Maintenance Olaparib for Metastatic Pancreatic Cancer. New England Journal of Medicine, 2019, 381, 1491-1493.	27.0	9
34	History of negative colorectal endoscopy and risk of rectosigmoid neoplasms at screening flexible sigmoidoscopy. International Journal of Colorectal Disease, 2006, 21, 105-113.	2.2	7
35	Cytokeratin immunostaining reveals micrometastasis in negative hematoxylin-eosin lymph nodes of resected stage I-II (pT2-pT3) colorectal cancer. Journal of Chemotherapy, 1997, 9, 119-120.	1.5	6
36	Assessing Generalizability of the Findings of Sigmoidoscopy Screening Trials: The Case of SCORE Trial. Journal of the National Cancer Institute, 2015, 107, 385.	6.3	4

#	Article	IF	CITATIONS
37	Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. Journal of Endocrinological Investigation, 2017, 40, 1265-1269.	3.3	4
38	Socioeconomic characteristics, life style, diabetes, family history of cancer and risk of pancreatic cancer. European Journal of Gastroenterology and Hepatology, 1993, 5, 367-372.	1.6	3
39	Lack of prognostic value of flow cytometric DNA content analysis in colorectal adenocarcinomas. European Journal of Cancer, 1994, 30, 569.	2.8	3
40	Informed Decisions Regarding Microsatellite Instability Testing: Need for an Intention-to-Screen Analysis. Journal of Clinical Oncology, 2010, 28, e537-e537.	1.6	3
41	In vitro effects of ranitidine on human lymphocyte functions. International Journal of Immunopharmacology, 1985, 7, 369.	1.1	2
42	Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months … why not 3 months?. Annals of Oncology, 2005, 16, 521-522.	1.2	2
43	Including Lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer. Annals of Oncology, 2017, 28, 2620-2621.	1.2	2
44	Functional analysis of a CDKN2A 5'UTR germline variant associated with pancreatic cancer development. PLoS ONE, 2017, 12, e0189123.	2.5	2
45	Streamlining universal screening for lynch syndrome (LS): Towards improved yield of genetic counseling (GC) Journal of Clinical Oncology, 2019, 37, 503-503.	1.6	2
46	Once-Only Sigmoidoscopy Screening for Colorectal Cancer: Incidence and Mortality Follow-up of the Italian Randomized Controlled Trial (SCORE). Gastroenterology, 2011, 140, S-15.	1.3	1
47	The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer—In Reply. JAMA Oncology, 2019, 5, 1512.	7.1	1
48	Absolute risk of rectosigmoid neoplasms at screening flexible sigmoidoscopy and history of negative colorectal endoscopy (SCORE trial-Italy). Gastroenterology, 2000, 118, A441.	1.3	0
49	Prostate cancer screening with PSA: new data, old debate. Oncology Reviews, 2009, 3, 133-135.	1.8	O